ECElisa Cavarsaschi

Elisa Cavarsaschi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elisa Cavarsaschi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early vs Delayed Steroid Treatment in Cerebral Amyloid Angiopathy–Related Inflammation

    by Giulia Negro, Michele Rossi, Elisa Cavarsaschi, Giorgia Orsani, Benedetta Storti, Mattia Losa, Nicolò Dell'ORto, Elena Moscatelli, Alessandro Francia, Giulia Marinoni, et al.


  • Open Access

    Iatrogenic Cerebral Amyloid Angiopathy–Related Inflammation

    by Benedetta Storti, Giulia Negro, Giorgia Orsani, Payam Tabaee Damavandi, Marco Donelli, Elisa Cavarsaschi, Elisa Conti, Gessica Sala, Chiara Paola Zoia, Carlo Ferrarese, et al.

    Variants of cerebral amyloid angiopathy (CAA) have been increasingly reported. Iatrogenic CAA (iCAA) is a subtype arising in patients with a history of neurosurgery. Current etiopathogenetic hypotheses focus on previous exposure to contaminated materials, such as cadaveric dura, followed by a prion-like mechanism. CAA-related inflammation (CAA-ri) represents the inflammatory variant of CAA, usually with a good response to immunosuppressive therapy. To date, the association between iCAA and CAA-ri has not been clarified yet. This study reports cases of iCAA evolving into CAA-ri, emphasizing the clinical and radiologic overlaps between these conditions. This retrospective observational study included patients with clinical and radiologic features of CAA-ri and a history of neurosurgical intervention, observed at 2 Italian neurologic centers. Patients were identified from CAA databases and screened for neurosurgical history before 1990. Eligible cases met diagnostic criteria for CAA-ri. Clinical data were anonymized and included surgical details, evidence of amyloid-β in the CNS (amyloid-PET, CSF biomarkers, genetic screening), and CAA-ri features (symptoms, imaging findings, treatment, and outcomes). We identified 6 patients with iCAA who developed clinical and instrumental features of CAA-ri during their follow-up. The mean age at neurosurgery was 17.2 years (range: <1-43) while the onset of CAA-ri occurred at 61.8 years (range: 48-79), with an average latency of 44.7 years (range: 36-59). Despite immunosuppressive treatment, 2 patients experienced a rapid decline in their clinical condition and deceased within a few months from CAA-ri onset. This study increases awareness about the potential occurrence of CAA-ri in patients with iCAA, confirming its aggressive nature and highlighting the importance of neuroinflammation in the pathogenesis of the disease. In these patients, CAA-ri seems to be associated with a severe clinical course and a poor response to steroid treatment, often resulting in a fatal outcome in the short term.